Cargando…

Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling. Myofibroblasts have been shown to arise from inters...

Descripción completa

Detalles Bibliográficos
Autores principales: Habiel, David M., Hogaboam, Cory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899580/
https://www.ncbi.nlm.nih.gov/pubmed/24478703
http://dx.doi.org/10.3389/fphar.2014.00002
_version_ 1782300595958317056
author Habiel, David M.
Hogaboam, Cory
author_facet Habiel, David M.
Hogaboam, Cory
author_sort Habiel, David M.
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling. Myofibroblasts have been shown to arise from interstitial fibroblasts, epithelial to mesenchymal transition of type II alveolar epithelial cells, and the differentiation of recruited fibrocytes. There are many mechanisms that are utilized by these cells for survival, proliferation, and persistent activation including up-regulation of cytokines [i.e., Interleukin 6 (IL-6) and C-C motif chemokine ligand 21 (CCL21)], cytokine receptors [i.e., Interleukin 6 Receptor 1 (IL-6R1), Glycoprotein 130 (gp130) and C-C Chemokine Receptor type 7 (CCR7)], and innate pattern recognition receptors [(PRRs; i.e., Toll Like Receptor 9 (TLR9)]. In this review, we will discuss the role of the cytokines IL-6 and CCL21, their receptors and the PRR, TLR9, in fibroblast recruitment, activation, survival, and differentiation into myofibroblasts in IPF.
format Online
Article
Text
id pubmed-3899580
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38995802014-01-29 Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis Habiel, David M. Hogaboam, Cory Front Pharmacol Pharmacology Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling. Myofibroblasts have been shown to arise from interstitial fibroblasts, epithelial to mesenchymal transition of type II alveolar epithelial cells, and the differentiation of recruited fibrocytes. There are many mechanisms that are utilized by these cells for survival, proliferation, and persistent activation including up-regulation of cytokines [i.e., Interleukin 6 (IL-6) and C-C motif chemokine ligand 21 (CCL21)], cytokine receptors [i.e., Interleukin 6 Receptor 1 (IL-6R1), Glycoprotein 130 (gp130) and C-C Chemokine Receptor type 7 (CCR7)], and innate pattern recognition receptors [(PRRs; i.e., Toll Like Receptor 9 (TLR9)]. In this review, we will discuss the role of the cytokines IL-6 and CCL21, their receptors and the PRR, TLR9, in fibroblast recruitment, activation, survival, and differentiation into myofibroblasts in IPF. Frontiers Media S.A. 2014-01-23 /pmc/articles/PMC3899580/ /pubmed/24478703 http://dx.doi.org/10.3389/fphar.2014.00002 Text en Copyright © 2014 Habiel and Hogaboam. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Habiel, David M.
Hogaboam, Cory
Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
title Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
title_full Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
title_fullStr Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
title_full_unstemmed Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
title_short Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
title_sort heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899580/
https://www.ncbi.nlm.nih.gov/pubmed/24478703
http://dx.doi.org/10.3389/fphar.2014.00002
work_keys_str_mv AT habieldavidm heterogeneityinfibroblastproliferationandsurvivalinidiopathicpulmonaryfibrosis
AT hogaboamcory heterogeneityinfibroblastproliferationandsurvivalinidiopathicpulmonaryfibrosis